Reporting from ASCO GU, Silke Gillessen (Manchester) comments on the results from major studies on Prostate Cancer that were presented during this meeting:
- Abstract 140 ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer; K. Fizazi
- Abstract 687: Phase 3 study of androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: The ARCHES trial; A.J. Armstrong